GILEAD SCIENCES, INC.
FOSTER CITY, CA · CIK 882095 · 13F filing filed 2026-08-03
No investment adviser registration (Form ADV) found for this filer. It may be a parent company whose subsidiaries are the registered advisers, a bank or insurer, or a manager based outside the US.
- Legal entityGILEAD SCIENCES, INC. (US)
$1.6bn
reported value
-22.1% vs Q1 2026
5positions
100.0%in top 10
0 new
1 added
0 reduced
1 sold out
vs Q1 2026
This report includes the holdings of 1 other manager that shares the investment decisions:
- Gilead Therapeutics A1 Unlimited Co – reports through this filing
Shares in two reports are counted once in each security's totals.
Holdings, Q2 2026
The small lines show how much was held over the last 4 quarters (adjusted for stock splits).
| Security | Value | Change |
|---|---|---|
| ARCUS BIOSCIENCES INC RCUS | $968.8m58.76% | Unchanged |
| GALAPAGOS NV LKFT | $500.2m30.34% | Unchanged |
| ASSEMBLY BIOSCIENCES INC ASMB | $136.8m8.30% | Added +471.7k |
| KYVERNA THERAPEUTICS INC KYTX | $36.8m2.23% | Unchanged |
| XILIO THERAPEUTICS INC COM | $6.2m0.38% | Unchanged |
Sold out since Q1 2026
| Security | Value then |
|---|---|
| ARCELLX INC ACLX | $771.7m6.7m shares |
Stakes above 5%
Companies where this manager has reported owning more than 5% of a class of shares, on Schedule 13D (may seek influence) or 13G (passive): its latest filing for each, from 19 Dec 2024 on.
| Company | Stake |
|---|---|
| ARCELLX INC ACLX · 13D · filed 2026-04-28 | 100.0% |
| GALAPAGOS NV LKFT · 13D · filed 2025-01-10 | 29.9% |
| ASSEMBLY BIOSCIENCES INC 13D · filed 2026-05-27 | 25.1% |
| ARCUS BIOSCIENCES INC RCUS · 13D · filed 2026-08-07 | 24.7%≈ $968.8m |
| XILIO THERAPEUTICS INC 13G · filed 2026-02-12 | 19.9% |